Bachelard H, Gardiner S M, Kemp P A, Bennett T
Unité de Recherche sur l'Hypertension, Centre de Recherche du CHUL, Université Laval, Ste-Foy, P.Q., Canada.
Neuropharmacology. 1994 Jun;33(6):769-88. doi: 10.1016/0028-3908(94)90117-1.
Carbachol was injected into the hypothalamic paraventricular nuclei (PVN) of conscious, unrestrained Long Evans rats, chronically instrumented with intravascular catheters and pulsed Doppler probes to assess changes in regional haemodynamics. Bilateral microinjections of carbachol (1 ng-1 microgram) produced increases in blood pressure, bradycardias and vasoconstrictions in renal, superior mesenteric and hindquarters vascular beds. In the presence of phentolamine, the bradycardic and hindquarters vasoconstrictor responses to carbachol were unchanged while the pressor response was smaller due to a reduction in the renal and the superior mesenteric vasoconstriction. In the presence of propranolol, the bradycardic response was reduced, but the pressor and renal vasoconstrictor responses were potentiated, whereas the superior mesenteric and hindquarter vasoconstrictions were not changed significantly. In the presence of phentolamine and propranolol, the heart rate and pressor responses, as well as the renal vasoconstriction, were unchanged, whereas the superior mesenteric vasoconstriction was reduced and the hindquarters vasoconstriction was potentiated. Together these results are consistent with an involvement of the sympathoadrenal system in the pressor response to carbachol injected into the PVN of untreated animals. They indicate that alpha-adrenoceptor-mediated vasoconstriction in the superior mesenteric vascular bed is a particularly important component in that regard. In the presence of the vasopressin antagonist, d(CH2)5(Tyr(Et))DAVP, alone or in combination with phentolamine and propranolol, the pressor response to carbachol was substantially reduced, while the renal and superior mesenteric vasoconstrictor effects were completely abolished; the bradycardia was not significantly affected by this treatment. These results indicate an important involvement of vasopressin in the cardiovascular responses to carbachol injected into the PVN of untreated animals. Moreover, in the presence of the vasopressin antagonist the hindquarters vascular bed showed a vasodilatation following PVN injection of carbachol; this effect was reversed to a vasoconstriction following combined i.v. pretreatment with the vasopressin antagonist, phentolamine and propranolol and hence was possibly due to circulating adrenaline acting on vasodilator beta 2-adrenoceptors. However, there was a residual hindquarters vasoconstriction raising the possibility that non-adrenergic, non-vasopressinergic vasoconstrictor mechanisms were influencing that vascular bed.
将卡巴胆碱注入清醒、未受束缚的Long Evans大鼠的下丘脑室旁核(PVN),这些大鼠长期植入血管内导管和脉冲多普勒探头以评估局部血流动力学变化。双侧微量注射卡巴胆碱(1纳克 - 1微克)可使血压升高、出现心动过缓,并使肾、肠系膜上动脉和后肢血管床发生血管收缩。在酚妥拉明存在的情况下,卡巴胆碱引起的心动过缓和后肢血管收缩反应不变,而由于肾和肠系膜上动脉血管收缩减弱,升压反应较小。在普萘洛尔存在的情况下,心动过缓反应减弱,但升压和肾血管收缩反应增强,而肠系膜上动脉和后肢血管收缩没有明显变化。在酚妥拉明和普萘洛尔同时存在的情况下,心率和升压反应以及肾血管收缩不变,而肠系膜上动脉血管收缩减弱,后肢血管收缩增强。这些结果共同表明,在未经处理的动物中,交感肾上腺系统参与了对注入PVN的卡巴胆碱的升压反应。它们表明,在这方面,α - 肾上腺素能受体介导的肠系膜上动脉血管床血管收缩是一个特别重要的组成部分。在存在血管加压素拮抗剂d(CH2)5(Tyr(Et))DAVP的情况下,单独或与酚妥拉明和普萘洛尔联合使用时,对卡巴胆碱的升压反应大幅降低,而肾和肠系膜上动脉血管收缩作用完全消失;这种处理对心动过缓没有显著影响。这些结果表明血管加压素在未经处理的动物对注入PVN的卡巴胆碱的心血管反应中起重要作用。此外,在存在血管加压素拮抗剂的情况下,后肢血管床在PVN注射卡巴胆碱后出现血管舒张;在用血管加压素拮抗剂、酚妥拉明和普萘洛尔联合静脉预处理后,这种作用逆转为血管收缩,因此可能是由于循环中的肾上腺素作用于血管舒张β2 - 肾上腺素能受体。然而,后肢仍有残余的血管收缩,这增加了非肾上腺素能、非血管加压素能血管收缩机制影响该血管床的可能性。